Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Greeks.live: Some Traders Optimistic About Altcoins' Weekend Performance, BTC Key Price Range at $66,000-$67,000

Greeks.live: Some Traders Optimistic About Altcoins' Weekend Performance, BTC Key Price Range at $66,000-$67,000

星球日报星球日报2025/04/20 13:28
Show original

Greeks.live macro researcher Adam released a brief for the Chinese community, noting a division in market sentiment. Some traders are optimistic about altcoins' weekend performance, believing SOL has increased more than tenfold from its bottom, while others warn this might be the last frenzy. The key price range for BTC is between $66,000 and $67,000, with several traders considering this area a concentration zone for short position stop losses.
The performance of altcoins has sparked debate; some argue that large gains in small-cap coins are normal, but some traders point out that calculating gains from the bottom can be misleading, suggesting SOL's greater increase results from its prior larger declines. In terms of market structure, traders have observed that CEXs have many buy orders supporting the price, most of which are withdrawn as the price approaches, indicating that exchanges may be deliberately guiding the price to trigger critical stop-loss levels.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Caribou shares plunge as company explores sale and cancels cancer project

October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)

路透社•2026/10/07 09:39